卵巢癌腹水的过继性细胞免疫治疗

对20例卵巢癌合并恶性腹水的患者提取股水中的肿瘤浸润淋巴细胞（TIL），在体外经重组白细胞介素2（rIL－2）诱导、扩增后回输病人腹腔。培养前后测定淋巴细胞亚群CD3、CD4、CDS、IL－2受体及细胞毒活性，并对TIL／rIL－2治疗前后的腹水病理细胞、CEA及CA125的变化进行监测。结果表明：腹水TIL经培养扩增后，CD8、IL－2受体及细胞毒活性明显增加（P＜0．01），腹水CEA及CA125水平均有不同程度下降．部分患者腹水病理细胞消失。经本法治疗腹水消失者占60％，总有效率80％，随访1～6月未见明显毒、副作用。

ADOPTIVE CELLULAR IMMUNOTHERAPY IN THE TREATMENT OF OVARIAN CARCINOMA WITH MALIGNANT ASCITES

This essay presents the treatment of 20 cases suffering from ovarian carcinoma complicated with malignant ascites. Tumor infiltrating lymphocytes (TIL) were abstracted and back-transfused after being induced and expanded in vitro via recombined interleukin-2 (rIL-2). The cytotoxic activity,phenotype and IL-2 receptor (IL-2R) were investigated in fresh,and CEA,CA125 as well as cytology of malignant ascites were determined anterior and posterior to the treatment with TIL/rIL-2. The results show that the cytotoxic sctivity of TIL and CDS,IL-2 as well as cell proliferation were remarkably improved,while CEA and CA125 levels were decreased in all the patients and partly became normal. The ascites disappeared in 60% with total effective rate of 80% and no serious toxicity or side effects were discovered during the follow-up visit of 1-6 months. It is concluded that the TIL. as a new kind of immunocyte,can be safely and effectively used in the treatment of ovarian carcinloma with malignant ascites.